Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients / 中华流行病学杂志
Chinese Journal of Epidemiology
;
(12): 470-476, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-969930
ABSTRACT
Tuberculosis (TB) prophylactic therapy for latent infection, which can reduce the risk for the development of active TB, is an important measure in TB control. China recommends prophylactic therapy for latent tuberculosis infection (LTBI) in some key populations to reduce the risk for TB. Contacts of patients with multi-drug and rifampicin-resistant TB (MDR/RR-TB) are at high risk for the infection with drug-resistant pathogen, however, no unified prophylactic therapy regimen has been recommended for LTBI due to exposure to MDR/RR-TB patients. This paper summarizes the current MDR/RR-TB prophylactic therapy regimen and its protection effect based on the results of the retrieval of literature, guidelines, expert consensus and technical specifications to provide reference for the prevention and control of LTBI.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Rifampin
/
Tuberculosis
/
China
/
Tuberculosis Resistente a Múltiples Medicamentos
/
Tuberculosis Latente
/
Antituberculosos
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Chino
Revista:
Chinese Journal of Epidemiology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS